Gabelli downgraded shares of Achaogen (NASDAQ:AKAO) from a buy rating to a hold rating in a research report report published on Friday morning, MarketBeat Ratings reports. Gabelli also issued estimates for Achaogen’s FY2018 earnings at ($3.30) EPS, FY2019 earnings at ($1.55) EPS, FY2020 earnings at ($0.80) EPS, FY2021 earnings at ($0.15) EPS and FY2022 earnings at $0.90 EPS.

Several other research analysts have also recently issued reports on AKAO. BidaskClub cut shares of Achaogen from a sell rating to a strong sell rating in a report on Wednesday, July 18th. Zacks Investment Research cut shares of Achaogen from a hold rating to a sell rating in a report on Wednesday, July 25th. Cowen restated a buy rating on shares of Achaogen in a report on Friday, July 27th. Needham & Company LLC cut shares of Achaogen from a buy rating to a hold rating in a report on Tuesday, August 7th. Finally, Stifel Nicolaus raised their target price on shares of Achaogen from $14.00 to $22.00 and gave the stock a buy rating in a report on Tuesday, August 7th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $14.81.

Shares of Achaogen stock traded down $0.40 on Friday, hitting $2.25. The stock had a trading volume of 1,656,391 shares, compared to its average volume of 579,029. The company has a debt-to-equity ratio of 0.42, a quick ratio of 3.79 and a current ratio of 3.79. Achaogen has a one year low of $2.10 and a one year high of $15.00. The stock has a market capitalization of $139.24 million, a price-to-earnings ratio of -0.71 and a beta of 0.67.

A number of hedge funds have recently made changes to their positions in AKAO. BlackRock Inc. lifted its stake in Achaogen by 2.1% in the first quarter. BlackRock Inc. now owns 2,898,459 shares of the biopharmaceutical company’s stock worth $37,536,000 after acquiring an additional 60,613 shares during the period. Allianz Asset Management GmbH lifted its stake in Achaogen by 81.8% in the first quarter. Allianz Asset Management GmbH now owns 92,781 shares of the biopharmaceutical company’s stock worth $1,202,000 after acquiring an additional 41,746 shares during the period. Sei Investments Co. purchased a new stake in Achaogen in the second quarter worth $423,000. Wedbush Securities Inc. lifted its position in Achaogen by 266.7% during the second quarter. Wedbush Securities Inc. now owns 91,850 shares of the biopharmaceutical company’s stock valued at $795,000 after buying an additional 66,800 shares during the period. Finally, Gabelli Funds LLC lifted its position in Achaogen by 18.6% during the second quarter. Gabelli Funds LLC now owns 206,400 shares of the biopharmaceutical company’s stock valued at $1,787,000 after buying an additional 32,400 shares during the period. 60.17% of the stock is owned by institutional investors.

Achaogen Company Profile

Achaogen, Inc, a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae.

See Also: Diversification Important in Investing

Analyst Recommendations for Achaogen (NASDAQ:AKAO)

Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.